文献速递青光眼

利用现有视野数据提升青光眼神经保护试验效能

Improving the Power of Glaucoma Neuroprotection Trials Using Existing Visual Field Data.
PubMed 文献 · Am J Ophthalmol · 2021-04-24

本文通过模拟研究评估在青光眼随机临床试验中优先选择测试可靠性高的患者能否提高试验效能。研究基于2804例患者至少10次视野检查的真实世界数据,计算反映测试间变异性的变异指数(VI),并模拟2年内规律视野检查及20%、30%、50%的神经保护效应。结果显示优先选择低VI患者可使30%和50%神经保护效应下所需样本量分别减少38%和49%(单眼设计),双眼设计下分别减少26%和38%。

要点

  • 优先纳入测试间变异性低的患者可显著提高青光眼神经保护试验的检验效能。
  • 在30%和50%神经保护效应下,单眼设计所需样本量分别减少38%和49%。
  • 双眼设计(含对照眼)下,优先选择低VI患者使样本量分别减少26%和38%。

核心结论

  • 选择测试间变异性低的患者可显著提高试验效能并减少所需样本量。

研究设计与样本

  • 方法学分析:基于2804例患者至少10次视野检查的真实世界数据,利用前6次检查平均偏差随时间回归残差计算变异指数(VI),并模拟2年内规律视野检查。

主要发现

  • 单眼设计中低神经保护效应在现有患者下无法达到80%效能。
  • 单眼设计中30%和50%神经保护效应下样本量分别减少38%和49%。
  • 双眼设计中30%和50%神经保护效应下样本量分别减少26%和38%。

关键数值与推荐

  • 主要结局为在80%效能下检测到显著差异(P < .05)所需样本量。
  • 模拟的神经保护效应为将观察到的进展速率降低20%、30%或50%。

临床怎么用

  • 在青光眼神经保护试验设计阶段,可考虑依据测试间变异性筛选患者以提高效能、减少样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Selecting reliable visual field (VF) test takers could improve the power of randomized clinical trials in glaucoma. We test this hypothesis via simulations using a large real world data set. DESIGN: Methodology analysis: assessment of how improving reliability affects sample size estimates. METHODS: A variability index (VI) estimating intertest variability was calculated for each subject using the residuals of the regression of the mean deviation over time for the first 6 tests in a series of at least 10 examinations for 2,804 patients. Using data from the rest of the series, we simulate VFs at regular intervals for 2 years. To simulate the neuroprotective effect (NE), we reduced the observed progression rate by 20%, 30%, or 50%. The main outcome measure was the sample size to detect a significant difference (P < .05) at 80% power. RESULTS: In the first experiment, we simulated a trial including one eye per subject, either selecting randomly from the database or prioritizing patients with low VI. We could not reach 80% power for the low NE with the available patients, but the sample size was reduced by 38% and 49% for the 30% and 50% NE, respectively. In the second experiment, we simulated 2 eyes per subject, one of which was the control eye. The sample size (smaller overall) was reduced by 26% and 38% for the 30% and 50% NE by prioritizing patients with low VI. CONCLUSIONS: Selecting patients with low intertest variability can significantly improve the power and reduce the sample size needed in a trial.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Montesano G, Quigley HA, Crabb DP, et al. Improving the Power of Glaucoma Neuroprotection Trials Using Existing Visual Field Data. Am J Ophthalmol. 2021. PMID: 33905747. doi:10.1016/j.ajo.2021.04.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。